US Patent Issued to LUDWIG INSTITUTE FOR CANCER RESEARCH on Nov. 18 for "A2/NY-ESO-1 specific t cell receptors and uses thereof" (Swiss Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,346, issued on Nov. 18, was assigned to LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (Zurich).

"A2/NY-ESO-1 specific t cell receptors and uses thereof" was invented by George Coukos (Epalinges, Switzerland), Melita Irving (Epalinges, Switzerland), Vincent Zoete (Epalinges, Switzerland) and Olivier Michielin (Lausanne, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The application provides genetically modified cell receptors (TCRs) specific for an epitope from cancer antigen NY-ESO-1. Also provided are related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells, inc...